Introduction Patients with schizophrenia have an elevated mortality risk compared to the
general population, with cardiovascular-related deaths being the leading cause. The role of …

Patients with schizophrenia have increased mortality and morbidity compared with the
general population. These patients have a 20-year shorter lifespan than peers without …

Objective: When a schizophrenia patient has an inadequate response to treatment with an
antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use …

Schizophrenia is a devastating illness that affects up to 1% of the population; it is
characterized by a combination of positive symptoms, negative symptoms, and cognitive …

One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

Objective: To identify the outcome of potentially serious adverse effects of clozapine,
particularly those frequently cited as reasons for clozapine discontinuation, and to …

Background: Numerous publications have provided evidence for clinically important
metabolic adverse effects of antipsychotics, but there is no systematic evaluation as to …

BACKGROUND: The metabolic syndrome (MS) is associated with increased risk for
diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia …

BACKGROUND: Antipsychotic medication is the cornerstone of schizophrenia treatment.
The impact of long-term exposure to antipsychotics on life-expectancy has recently received …

Background Weight gain is common for people with schizophrenia and this has serious
implications for health and well being. Objectives To determine the effects of both …